Artificial intelligence (AI) is steadily reshaping healthcare from all sides, introducing technologies we wouldn’t have thought possible five or 10 years ago.
It’s happening in the clinic (see HealthTap’s Doctor A.I.), it’s happening in diagnostics (see IBM Watson), and now it’s moving into earlier-stage drug discovery with Palo Alto, California-based twoXAR.
“In the couple years that we have been around, we’ve been told hundreds of times that computers cannot do this; that biology is too complex; that this will never work,” said Andrew A. Radin, CEO of the AI-driven biopharmaceutical company. “Yet, in every single disease program where we have run proof-of-concept studies on our novel AI-identified candidates, we have generated efficacious results across standard end points.”
Using a custom-built computational platform, twoXAR works to identify what it calls “unanticipated associations between drug and disease.” With the compounds of interest in hand, the team runs a series of preclinical studies to ‘de-risk’ them.
To read more see the full post at: TwoXAR merges artificial intelligence, drug discovery and… clones? - MedCity News